Drug drags.

While biosimilars promise to lower skyrocketing prices of biologics, the originals aren’t going down in the most lucrative market in the world without a fight (read: time-dragging patent litigation). This study reports that US insurance companies preferred biosimilars in only 14% of cases in 2019. | Chambers, JAMA 2020